Related Articles
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow
Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
Clinical analysis of 21-gene relapse score test in hormone receptor-positive early-stage breast cancer Corrigendum in /10.3892/ol.2021.12572
Oncotype testing in patients undergoing intraoperative radiation for breast cancer
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21‑gene recurrence score of 26‑30